Indivior to rename as Supernus after merger; supplemental proxy discloses Cantor valuation ranges
Indivior and Supernus disclosed supplemental proxy materials ahead of their merger. Indivior will be renamed Supernus post-merger. Cantor Fitzgerald's updated valuation ranges for Supernus are $50.55–$59.50 per share, and for Indivior, $24.20–$43.90 after adjustments. The supplement addresses stockholder concerns and denies wrongdoing.
How this was made
The 30-second read
Why it matters
The filing provides the first public valuation guidance for the combined entity, creating a clear arbitrage opportunity and setting expectations for shareholders.
Market read
Merger news with fresh valuation ranges offers actionable insight for traders before the Oct 15 shareholder vote.
What to watch
Potential antitrust review and integration risks are not addressed in the filing.
Background
Indivior and Supernus disclosed a supplemental proxy filing ahead of a special meeting, updating valuation ranges and confirming the merger structure.
Ticker impact
Indivior filed a supplemental proxy disclosing its merger with Supernus and new valuation ranges, making the merger the primary news for INDV.
likely upward pressure on INDV as investors price in the merger premium
The filing provides fresh valuation ranges and confirms the transaction, giving traders a concrete catalyst before the Oct 15 special meeting.
Supernus is the surviving entity in the Indivior merger and its implied per‑share valuation is disclosed, making the deal material for SUPN.
likely modest upside on SUPN as the market absorbs the implied $50.55‑$59.50 range
The supplemental proxy provides the first public valuation range for the combined company, creating a clear trading signal.
Market effects
Consolidation in the specialty pharma sector may prompt re‑valuation of peer companies.
U.S. biotech market may see modest ripple effects as investors assess merger premiums.
Limited to U.S. listed pharma stocks; no broader macro impact.
Counterpoint
If regulatory hurdles arise, the implied premium could evaporate, pressuring both stocks.
Key entities
- companyIndivior Pharmaceuticals, Inc.
Target of the merger, will be renamed Supernus.
- companySupernus Pharmaceuticals, Inc.
Surviving entity in the merger.
